Valsartan/hydrochlorothiazide - Novartis

Drug Profile

Valsartan/hydrochlorothiazide - Novartis

Alternative Names: Co-Dio; Co-Diovan; Co-Tareg; CoDiovan; Covals; Diovan HCT; KODIO EX; KODIO MD; Miten Plus; Nisisco; Provas comp; VAH631; Valsartan HCT

Latest Information Update: 07 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzothiadiazines; Branched-chain amino acids; Small molecules
  • Mechanism of Action Angiotensin receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 18 Nov 2011 Generic equivalent available in Austria, Germany, Denmark, Ireland, Italy, Netherlands, Sweden & France
  • 15 Nov 2011 Generic equivalent available in the UK for heart failure, hypertension and myocardial infarction
  • 01 May 2010 Efficacy data from the VALVET trial in Hypertension presented at the 25th Annual Scientific Meeting of the American Society of Hypertension (ASH-2010) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top